EU/3/18/2005: Orphan designation for the treatment of follicular lymphoma



On 21 March 2018, orphan designation (EU/3/18/2005) was granted by the European Commission to Quintiles Ireland Limited, Ireland, for tazemetostat for the treatment of follicular lymphoma.

In May 2018, Quintiles Ireland Limited changed name to IQVIA RDS Ireland Limited.

The sponsorship was transferred to Voisin Consulting S.A.R.L., France, in June 2019.

In October 2021, Voisin Consulting S.A.R.L. changed name to Voisin Consulting Life Sciences.

Key facts

Active substance
Intended use
Treatment of follicular lymphoma
Orphan designation status
EU designation number
Date of designation

Ipsen Pharma
65 Quai Georges Gorse
92100 Boulogne-Billancourt

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

April 2023The sponsorship was transferred from Voisin Consulting Life Sciences, France, to Ipsen Pharma, France.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating